In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...
CTS merges with the three Red Cross testing laboratories located in Charlotte, Portland and St. Loui...
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...